Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Show more
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK®...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.94 | -28.1428571429 | 14 | 14.22 | 10.05 | 55059 | 12.54669081 | CS |
4 | -2.7 | -21.1598746082 | 12.76 | 15.49 | 9.68 | 63667 | 11.70956549 | CS |
12 | 0.06 | 0.6 | 10 | 17.31 | 9.68 | 144235 | 12.48282471 | CS |
26 | -5.94 | -37.125 | 16 | 17.31 | 9.68 | 143408 | 12.20069786 | CS |
52 | -5.94 | -37.125 | 16 | 17.31 | 9.68 | 143408 | 12.20069786 | CS |
156 | -5.94 | -37.125 | 16 | 17.31 | 9.68 | 143408 | 12.20069786 | CS |
260 | -5.94 | -37.125 | 16 | 17.31 | 9.68 | 143408 | 12.20069786 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales